This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Quizartinib With Standard of Care Chemotherapy and...
Clinical trial

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)

Read time: 3 mins
Last updated:1st Sep 2016
Identifier: NCT02668653

Brief Summary:
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.

Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML).

Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy

Detailed Description:
This is a phase 3, randomized, double-blind, placebo-control global study. The purpose of this study is to compare the effect of quizartinib versus placebo (administered with standard induction and consolidation chemotherapy, then administered as continuation therapy for up to 36 cycles) on event-free survival in subjects with FLT3-internal tandem duplication (ITD) positive AML.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 536 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)
Actual Study Start Date: September 2016
Estimated Primary Completion Date: November 2020
Estimated Study Completion Date: November 2020

Arm:
- Experimental:
Chemotherapy plus quizartinib
- Active Comparator: Chemotherapy plus placebo

Category Value
Date last updated at source 2019-04-03
Study type(s) Interventional
Expected enrolment 536
Study start date 2016-09-01
Estimated primary completion date 2020-11-01

View full details